Navigation Links
'Clumping' Protein Linked to Return of Ovarian Cancer

Johns Hopkins scientists have discovered that women treated for ovarian cancer are at increased risk of a rapid and potentially fatal recurrence if their tumor cells have high// levels of a binding protein that triggers abnormal growth and slows down cell death, both hallmarks of malignancy.

“Now there’s the possibility that testing for NAC-1 protein in cancer tissue removed during surgery might identify women most at risk for recurrence and guide doctors and patients to greater vigilance and extended therapy,” said Ie-Ming Shih, M.D., Ph.D., associate professor of pathology at Johns Hopkins Kimmel Cancer Center. The research also suggests that drugs capable of blocking NAC-1 activity may be a useful strategy in preventing and treating recurrences as well.

A report on the research, the first to link NAC-1 to cancer, appears in the December 5 issue of the Proceedings of the National Academy of Sciences.

“Because recurrent cancers are often what really kill patients, and most ovarian cancer is diagnosed when it’s already advanced, our findings offer women a better chance of catching or preventing recurrent disease early and increasing survival,” says Shih.

An estimated at least 60 percent of advanced-stage ovarian cancer patients who appear to be disease-free after initial treatment develop recurrent disease, according to the researchers.

When the investigators compared levels of NAC-1 among primary and recurrent tumor samples taken from 338 ovarian cancer patients from two hospitals, they found that levels of NAC-1 were significantly higher in recurrent tumors compared with primary tumors taken from the same patient. Women whose primary cancers had high levels of NAC-1 were more likely to suffer a recurrence within one year.

Studying the functions of NAC-1, the researchers genetically modified cells so they made both NAC-1 and a component of the protein found at the ends of natural NAC-1 that is a binding site. In the modified cells, N130 capped off NAC-1 proteins disrupting their ability to bind with each other. This action can prevent tumor formation and kill cancer cells in experimental mice. Shih says that in the future, drugs that mimic N130 can be used to treat cancer.

Source-NewswiseSRM
'"/>




Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
3. Unravelling the secrets of ‘Huntingtin’ Protein - towards the treatment of ‘Huntingtons’ Disase
4. Unravelling the secrets of ‘Huntingtin’ Protein - towards the treatment of Huntingtins’ Disese
5. Protein in urine foresees heart disease
6. Levels Of Blood Proteins May Help Heart Disease Care
7. Protein signals need for heart surgery
8. Protein and fat improve memory
9. Clotting Protein plays a role in nerve repair
10. High Levels of Protein Linked to Brain Shrinkage
11. Protein can change worn muscle fibres
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2017)... ... June 28, 2017 , ... Guide to FDA and EU Medical ... matter on which side of the Atlantic devicemakers do business, this fully updated and ... follow. , In addition to the full text of the FDA’s regulations in 21 ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... a one-day corporate governance program for mid-market executives as a kick-off to the ... held Sunday, Sept. 24, 2017 on the University of Pennsylvania campus, followed by ...
(Date:6/28/2017)... ... June 28, 2017 , ... Doner Financial, a Cincinnati ... to insurance assistance and financial planning services, is announcing the commencement of a ... the region facing financial crisis. , Matthew 25: Ministries (M25M) is an international ...
(Date:6/27/2017)... , ... June 27, 2017 , ... DrugDev ... is whether they can trust the sponsor to pay them correctly and on time. ... and CROs establish payment strategies that encourage sites to work on their studies. , ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... From June ... The three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... industry, how to connect with today’s savvy consumer, and the latest in hearing ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... , June 12, 2017 Kineta, Inc., a ... announced Kineta Vice President of R&D and Head ... the Pandemic Preparedness for the Northwest and Beyond ... held on June 14, 2017 from 8:30-10:30 AM PDT at ... Dr. Bedard will be joined by ...
(Date:6/8/2017)... 8, 2017  Less than a month ago, amateur ... 200,000 companies, including hospital networks, in over 150 countries. ... of the largest online extortion attempts ever recorded. With ... it is imperative that providers understand where the risks ... this — and many other very real cyber threats.  ...
(Date:6/7/2017)... June 6, 2017  Diplomat Specialty Infusion Group, a brand of ... to its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound ... a low level of pollutants. ... consumers and better serve our Iowa patients," ...
Breaking Medicine Technology: